We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




World's First Proton Therapy Training Center Created

By HospiMedica International staff writers
Posted on 17 Mar 2009
The first center devoted exclusively to training in proton therapy has enrolled its first group of radiation oncologists, medical physicists, and dosimetrists in a rigorous training program that requires up to six months to complete. More...
Training for nurses, radiation therapists, and other personnel--from administrators to receptionists-- begins in March 2009.

The ProCure Training and Development Center (TDC) offers clinical, technical, interpersonal, and administrative training that pertains to all aspects of proton therapy treatment and patient care. "With our full-size treatment rooms and state-of-the art equipment, we simulate the total work environment for treating patients with proton therapy--with everything but the protons,” said John Cameron, Ph.D., founder, chairman and president of ProCure Treatment Centers, Inc. (Bloomington, IN, USA) and a physicist who is among the pioneers in proton therapy. "We believe we can promote the highest quality of patient care by providing ‘before-the-job training' rather than having to learn on the job.”

This first group of professionals will complete training in June 2009. They will be ready when ProCure's first proton therapy center opens in Oklahoma City (IA, USA) the summer of 2009. It will be the sixth proton center to open in the United States and will treat approximately 1,500 patients with cancer per year.

Proton therapy, an advanced form of radiation treatment for specific tumors, comprises ionizing radiation and has the same destructive mechanism in attacking cancer cells as photon radiation. The clinical benefits of proton therapy over conventional radiation therapy include: (1) Reduced occurrence of treatment related side effects due to the precision of the dose delivery and the resulting limited amount of radiation delivered to healthy tissues adjacent to the treatment volume. (2) Increased tumor control by being able to deposit a larger dose in the targeted volume. (3) Increased daily fraction dose that allows reduction of the number of fractions needed to treat a tumor. (4) Increased long-term patient survival rates for many types of tumors, due to improved local tumor control rate and reduction in the incidence of secondary tumors.

The ProCure TDC is a US$10-million, 20,000-square-foot facility that includes two treatment rooms and a fully operational four-dimensional (4D) computed tomography (CT) scanner. A dual inclined-beam room simulates the ability to bring the proton beam in from two angles; the gantry room simulates the full rotation of the proton beam around the patient. The TDC also has treatment planning areas, an immobilization device preparation area and lecture rooms.

"The training program is quite demanding,” said Tom Doyle, vice president of national training and education for ProCure. "Our class sizes are small--six to eight people--and participants are required to attend on-site classes where they learn how to operate all of the equipment, as well as participate in frequent web-based education programs. There's a challenging list of materials participants must read, self-training exercises, and of course, we do give exams,” Mr. Doyle said.

The curriculum includes general information about the science and application of proton therapy, as well as protocols for treating specific diseases, such as brain, head and neck, central nervous system, colorectal and prostate tumors. The special needs of pediatric patients are also addressed by the program.

Proton therapy, first used in a research setting in 1955, has become an established treatment option, and more than 55,000 patients worldwide have received the treatment. It is estimated that 250,000 people in the United States alone could benefit from proton therapy, yet the five American centers currently operating can only treat approximately 6,000 patients each year.

ProCure Treatment Centers was founded in 2005 to improve the lives of patients with cancer by increasing access to proton therapy. ProCure collaborates with leading radiation oncology practices and hospitals and provides management leadership and a comprehensive approach for the design, construction, financing, staffing, training, and day-to-day operations of world-class proton therapy centers

Related Links:
ProCure Treatment Centers


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.